ESPERION THERAPEUTICS INC (ESPR)
US29664W1053 - Common Stock
Esperion to Participate in Upcoming May Investor Conferences
Esperion to Participate in Upcoming May Investor Conferences
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following...
Esperion to Report First Quarter 2024 Financial Results on May 7
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – –...
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq...
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual...
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning.
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – ...
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase...
Esperion Therapeutics GAAP EPS of -$0.50 misses by $0.02, revenue of $32.25M beats by $3.55M (NASDAQ:ESPR)
Esperion Therapeutics reports Q4 financial results with a slight miss in EPS but strong revenue growth, driven by increased product sales in the US.
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new...
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial...
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024...